

13th August 2026

The Deputy Manager,
Department of Corporate Services,
BSE Limited,
P.J. Towers, Dalal Street, Fort,
Mumbai – 400001.

Scrip Code: 507486 (BSE)
Subject: Outcome of Board Meeting held on August 13, 2026

Dear Sir,

We hereby inform you that, in compliance with Regulation 30 read with Schedule III, Regulation 33, Regulation 42 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), the Board of Directors of Caprolactam Chemicals Limited (“the Company”), at their Meeting held today viz. August 13th, 2026, has inter-alia, approved the following:

Unaudited Standalone Financial Results for the quarter ended June 30th, 2026: Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a Statement of Unaudited Standalone Financial Results for the quarter ended June 30th, 2026 along with Limited Review Report submitted by the Statutory Auditors of the Company. The above financial results were upon recommendation of the Audit Committee approved by the Board of Directors at its meeting held on August 13th, 2026.

The meeting of the Board of Directors of the Company commenced at 12.00 p.m. and concluded at 1:00 p.m.

Kindly take the same on your record.

We request you to inform your members accordingly.

Thanking you.

Yours faithfully,
For Caprolactam Chemicals Limited



Zaver Shankarlal Bhanushali
Managing Director
DIN: 00663374



PULINDRA PATEL & CO.

CHARTERED ACCOUNTANTS

Office No. A-1004, Paras Business Center, Near Borivali Station East, Kasturba Road No.1,
Borivali (East), Mumbai – 66,

Office (Tel) + 022 28069664, 022-22056233, 022-68844594, +91 9322268243, Office (M) + 91 9619908533
Email : caoffice@pulindrapatel.com

Independent Auditor's Review Report on the Standalone Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Review Report to
The Board of Directors,
Caprolactam Chemicals Limited
Plot No. B-31, M.I.D.C.- Mahad,
Taluka – Mahad,
Dist. Raigad – 402302.

We have reviewed the quarterly unaudited standalone financial results of **M/S.CAPROLACTAM CHEMICALS LIMITED** (the company) for the, Quarter ended June 30, 2026 (the Statement”) attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations 2015 as amended (“Listing Regulations”).

This statement which is the responsibility of the Company’s Management and has been reviewed by the Audit committee and approved by the Board of Directors at their respective meetings held on 13th August, 2026, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial Reporting” (Ind AS 34), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

We conducted our review of the Statement in accordance with the standard on Review Engagement (SRE) 2410 ‘Review of Interim Financial Information performed by the Independent Auditor of the Entity’ issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the aforesaid Indian accounting standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

Attention is drawn to the fact that the figures for the three months ended 31 March 2025 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

Place: Mumbai
Date : 13th August, 2026

FOR PULINDRA PATEL & CO.
CHARTERED ACCOUNTANTS
FIRM REGN. NO. 115187W


Pulindra M. P.

PULINDRA PATEL
MEMBERSHIP No. 048991
UDIN: 26048991CPBHXL3985



Caprolactam Chemicals Limited
CIN No. L24110MH1988PLC049683

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026

PART I		(Rs. In Lakhs)			
	PARTICULARS	Quarter Ended			Year Ended
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		30-06-2026	31-03-2026	30-06-2025	31-03-2026
1	Revenue From Operation				
	Revenue from Operations	46.77	306.70	256.47	1,055.75
	Other Income	0.09	0.70	0.09	3.11
	Total Income	46.86	307.40	256.56	1,058.86
2	Expenses				
(a)	Cost of materials consumed	0.78	9.76	29.41	73.43
(b)	Purchase of stock - I trade	24.42	0.90	4.93	11.30
(c)	Change in inventories of Finished goods, work-in-progress and stock-intrade	-	-	3.75	3.75
(d)	Employee benefits expenses	9.22	17.29	11.27	51.63
(e)	Finance Costs	17.76	17.23	18.25	71.91
(f)	Depreciation, depletion and amortisation expenses	36.71	43.77	38.02	161.41
(g)	Other expenses	56.85	113.37	102.38	468.87
	Total Expenses	145.74	202.32	208.01	842.29
3	Profit / (Loss) before tax (1-2)	(98.88)	105.08	48.55	216.57
4	Tax Expense				
	Current tax	-	19.96	12.23	37.35
	Deferred tax	(0.02)	1.36	0.11	3.09
	Total Tax Expenses	(0.02)	21.32	12.34	40.44
5	Total Profit/(loss) After Tax (3-4)	(98.86)	83.76	36.21	176.12
6	Other Comprehensive Income (OCI)				
a)	Items That Will Not Be Reclassified To Profit or Loss		(0.83)		(0.83)
b)	Items That Will Be Reclassified To Profit or Loss		-		-
7	Total Comprehensive Income/(Loss) for the period (5+6)	(98.86)	82.93	36.21	175.29
8	Details of equity share capital				
9	Paid-up equity share capital	460.00	460.00	460.00	460.00
	Face value of equity share capital	10.00	10.00	10.00	10.00
10	Other Equity				
11	Earnings per share				
12	Earnings per equity share Rs.				
	Basic	(2.15)	1.82	0.79	3.83
	Diluted	(2.15)	1.82	0.79	3.83
13	Nominal value of share	10.00	10.00	10.00	10.00
	Disclosure of notes on finance results				
	1. The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13th August, 2026 and have been subjected to limited review by the Auditors.				
	2) These financial results of the Company have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.				
	3) The Standalone results of the company are available on the company's website http://caprolactum.co.in/ and also available on the websites of the BSE Ltd. And National Stock Exchange of India Ltd.				
	4) Figures for the previous quarter/ period have been regrouped/reclassified, wherever considered necessary. Figures for the previous quarter/ period have been regrouped/reclassified, wherever considered necessary.				
	5) The figures in Rs. Lakhs are rounded off to Two Decimals				
	Place: Mahad	FOR AND BEHALF OF THE BOARD OF DIRECTORS			
	Date: 13/08/2026	  Mrs. Zaver S Bhanushali Managing Director DIN- 00663374			